Sporadic fatal insomnia (sFI) is an extremely rare prion disease characterized by progressive inability to sleep, autonomic dysfunction and rapid neurodegeneration without the familial PRNP mutation found in fatal familial insomnia. It results from the conversion of the normal prion protein PrPC into abnormal, self-propagating PrPSc isoforms that accumulate within the thalamus and other brain regions.
Pathogenesis and Clinical Features
Unlike fatal familial insomnia, which is linked to a D178N mutation in the prion protein gene (PRNP) coupled with a methionine at codon 129, sFI arises sporadically through unknown mechanisms. Misfolded PrPSc converts endogenous PrPC, leading to aggregates that disrupt thalamic neurons and associated circuits. Neuropathology shows neuronal loss, gliosis and astrocytosis in the thalamus and inferior olives with relative preservation of cerebral cortex; PrP deposits can be detected by immunohistochemistry and western blotting. Clinically, sFI presents with progressively worsening insomnia, profound dysautonomia, endocrine disturbances, weight loss, ataxia and cognitive decline. Polysomnography reveals the loss of slow‑wave and rapid eye movement sleep, and electroencephalograms may show diffuse slowing rather than the periodic complexes typical of Creutzfeldt–Jakob disease. Patients gradually develop stupor and coma over months to a few years. Currently there is no effective therapy; symptomatic management with sedatives or clonazepam offers limited relief, and median survival after onset is about 24‑36 months.
Documented Cases and Diagnostic Insights
The first case of sporadic fatal insomnia was described in the late 1990s, prompting recognition of a distinct prion disease that mimics fatal familial insomnia but lacks the associated mutation. Fewer than three dozen cases have been reported worldwide, with patients often heterozygous at PRNP codon 129. Neuroimaging studies show bilateral thalamic hypometabolism on positron emission tomography and signal changes on magnetic resonance imaging. Cerebrospinal fluid assays for 14‑3–3 protein may be negative or weakly positive, complicating diagnosis. Families and physicians must rely on a combination of clinical features, sleep studies and genetic testing to exclude other prion disorders. Autopsy remains definitive for diagnosis. The rarity of sFI limits epidemiological insights, but spontaneous misfolding of PrPC or somatic mutations in the nervous system have been proposed. Preventive measures are not possible because the disease is not transmitted between individuals. Sporadic fatal insomnia underscores the variability of human prion diseases and highlights how the misfolding of a single host protein can selectively devastate the thalamus and sleep regulation networks. Continued surveillance and detailed case reports are essential for understanding its origin and for developing targeted therapies. Related Terms: fatal familial insomnia, sporadic Creutzfeldt–Jakob disease, Gerstmann–Sträussler–Scheinker syndrome, prion protein, thalamus